Layton JB, Anderson-Smits C, Ritchey ME, Chavan S, Souayah N. Treatment patterns of US patients with chronic inflammatory demyelinating polyradiculoneuropathy. Poster presented at the 2020 Virtual American Association of Neuromuscular and Electrodiagnostic Medicine Annual Meeting; October 2020. [abstract] Muscle Nerve. 2020 Oct; p.126.
John NM, Wright SJ, Gavan SP, Vass CM. The role of information provision in economic evaluations of non-invasive prenatal testing: a systematic review. Eur J Health Econ. 2019 Nov;20(8):1123-31. doi: 10.1007/s10198-019-01082-x
Fernandez M, Mordin M, Neighbors M, Tzivelekis S. A targeted literature review on the burden of chronic inflammatory demyelinating polyneuropathy. Poster presented at the 2019 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Conference; October 16, 2019. Austin, TX. [abstract] Muscle Nerve. 2019 Sep; p.112.
Kamptner NL, Teyber FH, Rockwood NJ, Drzewiecki D. Evaluating the efficacy of an attachment-informed psychotherapeutic program for incarcerated parents. J Prison Educ Reentr. 2017 Dec;4(2):62-81.
Wilson MR, Bergman A, Chevrou-Severac H, Selby R, Smyth M, Kerrigan MC. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom. Eur J Health Econ. 2017 Mar;19(2):229-40. doi: 10.1007/s10198-017-0879-5.
Williams V, Coles T, Gnanasakthy A, DeMuro C, Yarr S, Williams NJ, Lowes L, Alfano L, Tseng B. Psychometric validation of a patient-reported measure of physical functioning in sporadic inclusion body myositis. Muscle Nerve. 2016 Oct 13;54(4):658-65. doi: 10.1002/mus.25080
DeMuro C, Lewis S, Lowes L, Alfano L, Tseng B, Gnanasakthy A. Development of the sporadic inclusion body myositis physical functioning assessment (sIFA). Muscle Nerve. 2016 Oct;54(4):653-7. doi: 10.1002/mus.25079
Beard SM, von Scheele BG, Nuki G, Pearson IV. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ. 2013 May;Advance online publication.
Greiner W, Lehmann K, Earnshaw S, Bug C, Sabatowski R. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ. 2006 Dec 1;7(4):290-6.
Mansfield CA, Pattanayak SK, McDow W, MacDonald R, Halpin P. Shades of green: measuring the value of urban forests in the housing market. J Forest Econ. 2005 Dec;11(3):177-99. doi: 10.1016/j.jfe.2005.08.002
Cropper ML, Haile M, Lampietti J, Poulos C, Whittington D. The demand for a malaria vaccine: evidence from Ethiopia. J Dev Econ. 2004 Oct 1;75(1):303-18.
Lehmann K, Radbruch L, Gockel HH, Neighbors D, Nuyts G. Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Duragesic) with controlled release morphine. Eur J Health Econ. 2002;3:111-9. doi: 10.1007/s10198-002-0097-6.